Company: APXIF
Filing Date: 2025-03-31
Form Type: F-4/A
Source: 0001213900-25-026339
Chunk: 273

Company: APx Acquisition Corp. I
Filing Date: 2025-03-31
Form: F-4/A
Chunk 273
---
 plaque, coronary artery disease (“CAD”), and steatotic liver disease (the “MultiplAI Products”). Concurrently with the Restructuring, Parent has agreed to contribute to OmnigenicsAI certain receivables owed by MultiplAI to Parent pursuant to certain loan agreements. This binding term sheet was entered into in the context of negotiations relating to the termination of the MultiplAI Share Purchase Agreement. See “ Certain Agreements Related to the Business Combination — Reseller License Agreement” and “ Unaudited Pro Forma Combined Consolidated Financial Information — Adjustments to Unaudited Pro Forma Combined Consolidated Statement of Financial Position as of June 30, 2024.” On August 27, 2024, Parent, MultiplAI and the MultiplAI Shareholders (with APx’s consent) terminated the MultiplAI Share Purchase Agreement. As a result of such termination, OmnigenicsAI will not acquire MultiplAI, their business will not be combined pursuant to the Business Combination Agreement, and all rights and obligations of MultiplAI under the Business Combination Agreement ceased and terminated, subject to certain exceptions. For more information on the decision to terminate the MultiplAI Share Purchase Agreement, see “ — Decision to Terminate the MultiplAI Share Purchase Agreement.” Except as set forth above, no other terms of the Business Combination have been modified, and OmnigenicsAI and APx intend to complete the combination of our businesses (without the acquisition of MultiplAI) as set forth in the Business Combination Agreement. APx Board of Directors’ Reasons for the Approval of the Business Combination As described above, the APx Board, in evaluating the Business Combination, consulted with APx’s management and advisors. In reaching its unanimous decision to approve the Business Combination Agreement and the transactions contemplated by the Business Combination Agreement, the APx Board considered a range of factors, including, but not limited to, the factors discussed below. In light of the number and wide variety of factors considered in connection with its evaluation of the Business Combination, the APx Board did not consider it practicable to, and did not attempt to, quantify or otherwise assign relative weights to the specific factors that it considered in reaching its determination and supporting its decision. The APx Board viewed its decision as being based on the information available and the factors presented to and considered by it. In addition, individual directors may have given different weight to different factors. This explanation of APx’s reasons for the Business Combination and all other information presented in this section is forward